Investing in the 99%: How Health‑Tech Could Unlock Trillions in Underserved Markets

Investing in the 99%: How Health‑Tech Could Unlock Trillions in Underserved Markets

Medical AI has been called a breakthrough for modern healthcare — but it currently solves problems for the top 1% of hospitals and clinics in high‑income countries. The rest of the world — billions of people across low‑ and middle‑income countries (LMICs) — remain underserved. For investors, that '1% problem' is more than an ethical challenge; it is a roadmap to enormous, underpenetrated markets where health‑tech investment can generate financial returns and measurable impact.

Why this matters to investors

Emerging markets present a rare convergence: huge unmet medical needs, rapidly improving digital infrastructure, and growing public and private capital targeting healthcare. Scalable diagnostics powered by affordable medical AI can unlock these markets by reducing per‑test costs, speeding diagnosis, and enabling task‑shifting to less‑specialized staff. For investors focused on investing strategy across healthcare infrastructure, market penetration, and impact investing, the opportunity is to fund business models that translate clinical algorithms into reachable, repeatable distribution systems.

Understanding the 1% problem as a strategic lens

The '1% problem' highlights a concentration of innovation and deployment in elite systems: advanced imaging centers, specialist hospitals, and wealthy clinics. This concentration arises from three factors: regulatory rigor and liability concerns, the need for high‑quality data and integration, and procurement cycles that favor incumbents. Investors can flip this problem into a strategy by prioritizing solutions designed for constrained environments: robustness to variable data quality, low bandwidth deployment, simple user interfaces, and alternative regulatory pathways.

Market size and economics

Aggregate demand for diagnostics and basic imaging in LMICs is massive. Replace high per‑unit margins in elite settings with low‑margin, high‑volume models and the revenue math changes dramatically. Key economics to model:

• Price per diagnostic event vs. utilization rate — small fees at scale can create sustainable revenues.
• Hardware amortization and device sharing — one ultrasound or X‑ray device can serve thousands of patients when paired with robust AI.
• Variable OPEX — local training, maintenance, and data cost savings through federated learning.

Business models that scale in emerging markets

Not every health‑tech model built for high‑income systems is suitable for emerging markets. Below are business models that investors should evaluate for attractive unit economics and scalability:

1. SaaS + Edge AI: Cloud subscription for model updates combined with edge inference to operate offline. This minimizes bandwidth and regulatory complexities around cross‑border data transfer.
2. Device + Software Bundles: Selling or leasing low‑cost imaging devices pre‑loaded with AI reduces integration costs and accelerates adoption.
3. Pay‑per‑use Diagnostics: Transactional pricing tied to each diagnostic event works well where per‑capita healthcare spend is low but volumes are high.
4. Franchise Diagnostic Hubs: Local entrepreneur partners run standardized diagnostic centers using shared AI and procurement, improving cost efficiency and market penetration.
5. Public‑Private Partnership (PPP) Service Contracts: Governments contract with providers to deliver screening programs at scale — investors can finance capex and operationalize services in return for service fees or availability payments.

Regulatory pathways and managing regulatory risk

Regulatory risk is among the top concerns for medical AI investors. Yet the pathway for approval and safe deployment in emerging markets can be pragmatic and faster when planned correctly. Key considerations:

• Leverage international certifications: CE marking and FDA clearance remain valuable signals. Many LMIC regulators accept or fast‑track systems with these clearances.
• WHO prequalification and regional harmonization: For devices and diagnostics, WHO prequalification and regional approvals (e.g., African Medicines Agency in the future, or existing regional bodies) can accelerate procurement by public health systems.
• Local validation studies: Clinical validation in local populations is necessary to prove performance across different demographics and disease prevalence.
• Risk classification and post‑market surveillance: Design models for continuous monitoring and model updating; implement capture of local outcomes to maintain safety and efficacy.

Investors should budget for regulatory timelines and prioritize companies that plan regulatory strategy from day one. When possible, structure financing to support clinical trials and prequalification processes as discrete, fundable milestones.

Scalable distribution partnerships: the core multiplier

Market penetration hinges on distribution. Scalable diagnostics require partnerships across sectors:

• Government health systems: Ministries of Health are often the largest buyers for national screening programs. Long procurement cycles but huge scale.
• Non‑governmental organizations and global health agencies: NGOs can run pilots and accelerate adoption in target communities.
• Local private clinic networks and franchisors: These partners can replicate a service model quickly across cities.
• Telecoms and last‑mile distribution: Telcos can provide connectivity, billing platforms, and physical reach in rural areas.
• Medical device distributors and logistics operators: Partners adept at equipment maintenance and supply chain reduce failure rates and downtime.

Practical partnership playbook for investors:

1. Identify anchor public buyers (national programs or regional procurement agencies).
2. Partner with an NGO or foundation to co‑fund a proof‑of‑concept in 1–3 representative sites.
3. Secure a telco or fintech partner for digital payments and remote monitoring.
4. Sign exclusivity for distribution in targeted regions in exchange for market development support.

For examples of broader macro playbooks that affect market decisions, see how localized risks influence investment timing in related sectors like logistics and infrastructure: How Localized Weather Events Influence Market Decisions. For building resilient teams to scale operations in new markets, consider lessons from workforce transformations: Embracing Change: How Tech Companies Can Navigate Workforce Transformations Post‑Acquisition.

Financing structures: blending returns with impact

Investors should be creative with capital stacks. A combination of concessional capital, commercial equity, and outcome‑based financing can de‑risk early deployment:

• Development Finance Institution (DFI) equity or guarantees: DFIs can provide mezzanine capital or credit guarantees to attract private co‑investors.
• Grants for validation: Philanthropic grants or innovation prizes can fund local trials and regulatory submissions.
• Pay‑for‑performance contracts: Governments or donors pay per screened patient or per case detected, aligning incentives and reducing demand risk.
• Impact bonds and blended finance: These tools can bridge the gap between early pilots and scaled procurement.

Due diligence checklist for investors

Before allocating capital, use this checklist to assess companies and deals. These are practical, actionable items you can require in term sheets or investment memoranda:

• Clinical validation in ≥2 local populations and evidence of generalizability.
• Regulatory clearances or a documented pathway to regional approvals and WHO prequalification.
• Realistic go‑to‑market plan with signed letters of intent from distribution partners (govts, NGOs, telcos).
• Unit economics model showing break‑even utilization rates under different pricing tiers (SaaS, pay‑per‑use, capex lease).
• Plan for post‑market surveillance and model updating, including data governance and privacy compliance.
• Exit strategy: acquisition targets (local device makers, regional healthcare conglomerates) or scale to cash‑flow positive service provider.

Mitigating key risks

Some of the main risks and mitigations are:

• Regulatory risk: Mitigate via phased approvals, pilot outcomes, and partnering with local clinical champions.
• Infrastructure constraints: Use edge computing and battery‑powered devices; partner with logistics firms and local clinics to ensure uptime.
• Market adoption: Invest in training programs and user centrism; embed AI as a decision support tool, not a replacement.
• Currency and political risk: Hedge exposures, use local currency revenue models, and secure government contracting where possible.

Case example: a hypothetical scalable diagnostics roll‑out

Imagine a telco‑partnered roll‑out of an AI‑assisted ultrasound for maternal health across a Southeast Asian country:

1. Phase 1 — Pilot: 10 community clinics run a 6‑month pilot funded by an NGO grant to validate clinical performance and workflow integration.
2. Phase 2 — Validation and Approval: Local validation data used to secure regional approval and WHO endorsement; DFI provides a loan to purchase devices.
3. Phase 3 — Scale: Telco bundles connectivity and micro‑payments, local entrepreneurs run franchise diagnostic hubs, and the ministry of health adopts the program for rural antenatal screening with pay‑for‑performance payments.
4. Exit: A strategic buyer (global medical device manufacturer or regional healthcare chain) acquires the operating business after it reaches strong cash flow and national contracts.

Where investors should start today

Actionable next steps for investors seeking exposure to this space:

• Map 3 target countries with favorable demographics, improving digital infrastructure, and receptive regulators.
• Allocate a small ticket to a fund or SPV focused on medical AI for emerging markets to diversify country and technology risk.
• Engage with DFIs, global health foundations, and local distributors to co‑design pilots that de‑risk the first 12–24 months.
• Request measurable KPIs in term sheets: cost per screened patient, detection rate improvement, device uptime, and local training throughput.

Conclusion

Medical AI’s 1% problem is not merely a critique — it is an investor’s blueprint. By prioritizing business models that optimize for scale and low cost, mapping practical regulatory pathways, and building deep distribution partnerships across public and private sectors, investors can tap into the trillions of dollars in unmet healthcare demand across emerging markets. The payoff is both monetary and societal: scalable diagnostics can bring basic health services to the 99% — creating sustainable returns and measurable impact.

For broader macro context on economic power plays and how global initiatives influence market entry strategies, see our coverage of global economic forums: Davos: The Economic Power Play Amidst Global Turbulence.